Skip to main content

Advertisement

Log in

Juvenile Dermatomyositis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Juvenile dermatomyositis (JDM) is a rare, often chronic autoimmune disease with onset during childhood. It is characterized by weakness in proximal muscles and pathognomonic skin rashes. Although the etiology remains unclear, it has been proposed that JDM is caused by a vasculopathy within the muscle tissue and multiple other organ systems of genetically susceptible individuals, possibly in response to environmental triggers. The goals of treatment include control of the underlying inflammatory myositis and prevention and/or treatment of complications (eg, contractures and calcinosis). Delayed treatment may lead to poorer outcome in terms of disease course and calcinosis. The course in JDM is variable. Monocyclic disease occurs in about one third of patients. These patients have a good response to standard therapy. Early recognition and aggressive immunosuppressive treatment result in improved prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. McCann LJ et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)—clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford). 2006;45(10):1255–60.

    Article  CAS  Google Scholar 

  2. Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995;34(8):732–6.

    Article  PubMed  CAS  Google Scholar 

  3. Mendez EP et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49(3):300–5.

    Article  PubMed  Google Scholar 

  4. Compeyrot-Lacassagne S, Feldman BM. Inflammatory myopathies in children. Pediatr Clin North Am. 2005;52(2):493–520. vi–vii.

    Article  PubMed  Google Scholar 

  5. Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am. 2002;28(4):833–57.

    Article  PubMed  CAS  Google Scholar 

  6. Reed AM, Pachman L, Ober C. Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501. Hum Immunol. 1991;32(4):235–40.

    Article  PubMed  CAS  Google Scholar 

  7. Mamyrova G et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum. 2006;54(12):3979–87.

    Article  PubMed  CAS  Google Scholar 

  8. Pachman LM et al. Increased frequency of HLA-B8 in juvenile dermatomyositis. Lancet. 1977;2(8050):1238.

    Article  PubMed  CAS  Google Scholar 

  9. Pachman LM et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum. 2000;43(10):2368–77.

    Article  PubMed  CAS  Google Scholar 

  10. Rider LG et al. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clin Exp Immunol. 2000;121(1):47–52.

    Article  PubMed  CAS  Google Scholar 

  11. Massa M et al. Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum. 2002;46(11):3015–25.

    Article  PubMed  CAS  Google Scholar 

  12. Pachman LM et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum. 2005;53(2):166–72.

    Article  PubMed  Google Scholar 

  13. Manlhiot C et al. Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset. Rheumatology (Oxford). 2008;47(4):526–9.

    Article  CAS  Google Scholar 

  14. Khanna S, Reed AM. Immunopathogenesis of juvenile dermatomyositis. Muscle Nerve. 2010;41(5):581–92.

    Google Scholar 

  15. Li CK et al. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol. 2004;31(3):605–9.

    PubMed  CAS  Google Scholar 

  16. • Niewold TB et al. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum. 2009;60(6):1815–24. This study examined serum IFN-α activity in a cohort of children with JDM to determine relationships between IFN-α and indicators of disease activity and severity. Serum IFN-α activity was associated with higher serum levels of muscle-derived enzymes and a shorter duration of untreated disease in patients with newly diagnosed JDM, and was inversely correlated with measures of chronic disease activity at 36 months after diagnosis.

    Article  PubMed  CAS  Google Scholar 

  17. Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol Rep. 2010;12(3):198–203.

    Google Scholar 

  18. • Bilgic H et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 2009;60(11):3436–46. This study evaluated the capacity of IFN-dependent peripheral blood gene and chemokine signatures and levels of proinflammatory cytokines to serve as biomarkers for disease activity in adult DM and JDM. Serum IL-6 production and the type 1 IFN gene signature were found to be candidate biomarkers for disease activity in adult DM and JDM.

    Article  PubMed  CAS  Google Scholar 

  19. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.

    Article  PubMed  CAS  Google Scholar 

  20. Brown VE et al. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford). 2006;45(8):990–3.

    Article  CAS  Google Scholar 

  21. Tse S et al. The arthritis of inflammatory childhood myositis syndromes. J Rheumatol. 2001;28(1):192–7.

    PubMed  CAS  Google Scholar 

  22. Akikusa JD et al. Eye findings in patients with juvenile dermatomyositis. J Rheumatol. 2005;32(10):1986–91.

    PubMed  Google Scholar 

  23. Cook CD, Rosen FS, Banker BQ. Dermatomyositis and Focal Scleroderma. Pediatr Clin North Am. 1963;10:979–1016.

    PubMed  CAS  Google Scholar 

  24. Schmeling H, et al. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. Rheumatology (Oxford). 2010. doi:10.1093/rheumatology/keq407.

  25. Smith RL et al. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol. 2004;31(8):1644–9.

    PubMed  Google Scholar 

  26. Feldman BM et al. Nailfold capillaries as indicators of disease activity in juvenile idiopathic inflammatory myopathies (JIIM). Arthritis Rheum. 1999;42(9):S181.

    Google Scholar 

  27. Spencer CH et al. Course of treated juvenile dermatomyositis. J Pediatr. 1984;105(3):399–408.

    Article  PubMed  CAS  Google Scholar 

  28. Huber AM et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43(3):541–9.

    Article  PubMed  CAS  Google Scholar 

  29. Blane CE et al. Patterns of calcification in childhood dermatomyositis. Am J Roentgenol. 1984;142(2):397–400.

    CAS  Google Scholar 

  30. Bowyer SL et al. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr. 1983;103(6):882–8.

    Article  PubMed  CAS  Google Scholar 

  31. Huemer C et al. Lipodystrophy in patients with juvenile dermatomyositis—evaluation of clinical and metabolic abnormalities. J Rheumatol. 2001;28(3):610–5.

    PubMed  CAS  Google Scholar 

  32. Rouster-Stevens KA et al. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum. 2008;59(2):222–6.

    Article  PubMed  CAS  Google Scholar 

  33. Pachman LM, Cooke N. Juvenile dermatomyositis: a clinical and immunologic study. J Pediatr. 1980;96(2):226–34.

    Article  PubMed  CAS  Google Scholar 

  34. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol. 1993;100(1):124S–7S.

    Article  PubMed  CAS  Google Scholar 

  35. •• Stringer E, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol. 2010;37(9):1953–1961. This study assessed the therapeutic approaches of North American pediatric rheumatologists to inform future studies of therapy in JDM. For most North American pediatric rheumatologists, corticosteroids and methotrexate appear to be the standard of care for typical cases of JDM. There is variability, however, in the route of administration of corticosteroids and use of IVIG and hydroxychloroquine.

  36. •• Huber AM, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children’s Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken). 2010;62(2):219–25. This study used JDM survey data and expert opinion to develop a small number of consensus treatment protocols that reflect current initial treatment of moderately severe JDM. Three protocols that described the first 2 months of treatment were developed. All protocols included corticosteroids and methotrexate.

  37. Ramanan AV et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52(11):3570–8.

    Article  PubMed  CAS  Google Scholar 

  38. Seshadri R et al. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum. 2008;59(7):989–95.

    Article  PubMed  CAS  Google Scholar 

  39. Dalakas MC et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27):1993–2000.

    Article  PubMed  CAS  Google Scholar 

  40. Pullenayegum EM et al. Fitting marginal structural models: estimating covariate-treatment associations in the reweighted data set can guide model fitting. J Clin Epidemiol. 2008;61(9):875–81.

    Article  PubMed  Google Scholar 

  41. (PRINTO), P.R.I.N.T.O. Juvenile Dermatomyositis Trial. 2010 cited; Available from: http://www.printo.it/project_ongoing_detail.asp?ProjectID=14.

  42. Riley P et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004;43(4):491–6.

    Article  CAS  Google Scholar 

  43. Riley P et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford). 2008;47(6):877–80.

    Article  CAS  Google Scholar 

  44. Cooper MA et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007;56(9):3107–11.

    Article  PubMed  CAS  Google Scholar 

  45. Oddis CV et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM) - The RIM study. Arthritis Rheum. 2010;62(10)Suppl.

  46. Rouster-Stevens K. A., et al. Mycophenolate mofetil: A possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(10):1446–51.

    Google Scholar 

  47. Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol. 2008;27(11):1469–71.

    Article  PubMed  Google Scholar 

  48. Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol. 1989;16(12):1545–7.

    PubMed  CAS  Google Scholar 

  49. Ruperto N et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford). 2003;42(12):1452–9.

    Article  Google Scholar 

  50. Miller FW et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2001;40(11):1262–73.

    Article  CAS  Google Scholar 

  51. •• Rider, L.G., et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2010;62(4):465–72. This study validated MMT for strength assessment in JDM and adult DM and polymyositis. Consensus was reached to use a subset of eight muscles (neck flexors, deltoids, biceps, wrist extensors, gluteus maximus and medius, quadriceps, and ankle dorsiflexors) that performed as well as the total and proximal MMT, and had good face validity and ease of assessment.

  52. Huber AM et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum. 2004;50(5):1595–603.

    Article  PubMed  Google Scholar 

  53. Huber AM et al. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol. 2001;28(5):1106–11.

    PubMed  CAS  Google Scholar 

  54. • Rider LG et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum. 2009;60(11):3425–35. This study validated the MDI in juvenile and adult myositis, described the degree and types of damage, and developed predictors of damage. Damage was found to be common in myositis after a median duration of 5 years in patients with adult-onset disease and 6.8 years in patients with juvenile-onset disease. The MDI has good content, construct, and predictive validity in juvenile and adult myositis.

    Article  PubMed  Google Scholar 

  55. •• Ruperto, N. et al. The pediatric rheumatology international trials organization provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(11):1533–41. This study developed a provisional definition for the evaluation of response to therapy in JDM based on the PRINTO JDM core set of variables. The top definition of improvement was at least 20% improvement from baseline in three of six core set variables, with no more than one of the remaining worsening by more than 30% (which cannot be muscle strength).

  56. Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum. 2008;58(11):3585–92.

    Article  PubMed  Google Scholar 

  57. •• Ravelli, A. et al, Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1): p. 63–72. This study investigated the long-term outcome and prognostic factors of JDM through a multinational, multicenter study. Many patients had continued disease activity and cumulative damage at follow-up. A chronic course was the strongest predictor of poor prognosis. These findings highlight the need for treatment strategies that enable better control of disease activity over time and the reduction of nonreversible damage.

  58. Sanner H, et al. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case-control study. Arthritis Care Res (Hoboken). 2010;62(8):1103–11

    Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Brian M. Feldman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Batthish, M., Feldman, B.M. Juvenile Dermatomyositis. Curr Rheumatol Rep 13, 216–224 (2011). https://doi.org/10.1007/s11926-011-0167-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-011-0167-9

Keywords

Navigation